Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1-3

Agnieszka Pluta, Paweł Stróżecki, Jacek Kęsy, Kinga Lis, Beata Sulikowska, Grażyna Odrowąż-Sypniewska, Jacek Manitius, Agnieszka Pluta, Paweł Stróżecki, Jacek Kęsy, Kinga Lis, Beata Sulikowska, Grażyna Odrowąż-Sypniewska, Jacek Manitius

Abstract

Introduction: Chronic kidney disease (CKD) is accompanied by inflammation. The aim of this study was to evaluate the effect of 6-month supplementation with omega-3 acids on selected markers of inflammation in patients with CKD stages 1-3.

Methods: Six-month supplementation with omega-3 acids (2 g/day) was administered to 87 CKD patients and to 27 healthy individuals. At baseline and after follow-up, blood was taken for C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) concentration and white blood cell (WBC) count. Serum concentration of omega-3 acids-eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA)-was determined using gas chromatography. And 24-hour urinary collection was performed to measure MCP-1 excretion.

Results: After six-month omega-3 supplementation, ALA concentration increased in CKD patients and in the reference group, while EPA and DHA did not change. At follow-up, a significant decrease in urinary MCP-1 excretion in CKD (p = 0.0012) and in the reference group (p = 0.001) was found. CRP, serum MCP-1, and WBC did not change significantly. The estimated glomerular filtration rate (eGFR) did not change significantly in the CKD group.

Conclusions: The reduction of urinary MCP-1 excretion in the absence of MCP-1 serum concentration may suggest a beneficial effect of omega-3 supplementation on tubular MCP-1 production.

Trial registration: This study was registered in ClinicalTrials.gov (identifier: NCT02147002).

References

    1. Locatelli F., Canaud B., Eckardt K.-U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging treat to patient outcome. Nephrology Dialysis Transplantation . 2003;18(7):1272–1280. doi: 10.1093/ndt/gfg074.
    1. Amdur R. L., Feldman H. I., Gupta J., et al. Inflammation and Progression of CKD: The CRIC Study. Clinical Journal of the American Society of Nephrology. 2016;11(9):1546–1556. doi: 10.2215/CJN.13121215.
    1. Amparo F. C., Kamimura M. A., Molnar M. Z., et al. Diagnostic validation and prognostic significance of the Malnutrition-Inflammation Score in nondialyzed chronic kidney disease patients. Nephrology Dialysis Transplantation . 2015;30(5):821–828. doi: 10.1093/ndt/gfu380.
    1. Vaziri N. D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. Journal of Renal Nutrition. 2010;20(5, supplement):S35–S43. doi: 10.1053/j.jrn.2010.05.010.
    1. Swaminathan S., Shah S. V. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney International. 2011;80(5):453–463. doi: 10.1038/ki.2011.178.
    1. Pasceri V., Willerson J. T., Yeh E. T. H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):2165–2168. doi: 10.1161/01.CIR.102.18.2165.
    1. Stehouwer C. D. A. Endothelial dysfunction in diabetic nephropathy: State of the art and potential significance for non-diabetic renal disease. Nephrology Dialysis Transplantation . 2004;19(4):778–781. doi: 10.1093/ndt/gfh015.
    1. Pecoits-Filho R., Bárány P., Lindholm B., Heimbürger O., Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrology Dialysis Transplantation . 2002;17(9):1684–1688. doi: 10.1093/ndt/17.9.1684.
    1. Vianna H. R., Soares C. M. B. M., Silveira K. D., et al. Cytokines in chronic kidney disease: Potential link of MCP-1 and dyslipidemia in glomerular diseases. Pediatric Nephrology. 2013;28(3):463–469. doi: 10.1007/s00467-012-2363-x.
    1. Viedt C., Orth S. R. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrology Dialysis Transplantation . 2002;17(12):2043–2047. doi: 10.1093/ndt/17.12.2043.
    1. Kishimoto T. Interleukin-6: discovery of pleiotropic cytokine. Arthritis Research & Therapy. 2006;8(supplement 2, article S2)
    1. Viedt C., Vogel J., Athanasiou T., et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-κB and activator protein-1. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22(6):914–920. doi: 10.1161/01.ATV.0000019009.73586.7F.
    1. Sicińska P., Pytel E., Kurowska J., Koter-Michalak M. Supplementation with omega fatty acids in various diseases. Postepy Higieny i Medycyny Doswiadczalnej. 2015;69:838–852. doi: 10.5604/17322693.1162673.
    1. Fassett R. G., Gobe G. C., Peake J. M., Coombes J. S. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. American Journal of Kidney Diseases. 2010;56(4):728–742. doi: 10.1053/j.ajkd.2010.03.009.
    1. Lee S. M., An W. S. Cardioprotective effects of ω-3 PUFAs in chronic kidney disease. BioMed Research International. 2013;2013:8. doi: 10.1155/2013/712949.712949
    1. Deike E., Bowden R. G., Moreillon J. J., et al. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients. Journal of Renal Nutrition. 2012;22(6):572–577. doi: 10.1053/j.jrn.2011.10.036.
    1. Levey A. S., Stevens L. A., Schmid C. H., et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
    1. Bondia-Pons I., Castellote A. I., López-Sabater M. C. Comparison of conventional and fast gas chromatography in human plasma fatty acid determination. Journal of Chromatography B. 2004;809(2):339–344. doi: 10.1016/j.jchromb.2004.07.002.
    1. Gluba-Brzózka A., Michalska-Kasiczak M., Franczyk B., et al. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids in Health and Disease. 2016;15(1, article 32) doi: 10.1186/s12944-016-0191-x.
    1. Pluta A., Strózecki P., Krintus M., Odrowąz-Sypniewska G., Manitius J. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1-3. Renal Failure. 2015;37(7):1105–1110. doi: 10.3109/0886022X.2015.1061669.
    1. Huang X., Lindholm B., Stenvinkel P., Carrero J. J. Dietary fat modification in patients with chronic kidney disease: N-3 fatty acids and beyond. Journal of Nephrology. 2013;26(6):960–974. doi: 10.5301/jn.5000284.
    1. Aukema H. M. Lipids in chronic kidney disease: Alterations and interventions. Lipid Technology. 2013;25(9):207–209. doi: 10.1002/lite.201300296.
    1. Lauretani F., Maggio M., Pizzarelli F., et al. Omega-3 and renal function in older adults. Current Pharmaceutical Design. 2009;15(36):4149–4156. doi: 10.2174/138161209789909719.
    1. Castellani S., Paniccia R., Di Serio C., et al. Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure. Journal of the American College of Cardiology. 2003;42(1):133–139. doi: 10.1016/S0735-1097(03)00511-4.
    1. Nowak J. Z. Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Postepy Higieny i Medycyny Doswiadczalnej. 2010;64:115–132.
    1. Hung A. M., Booker C., Ellis C. D., et al. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrology Dialysis Transplantation . 2015;30(2):266–274. doi: 10.1093/ndt/gfu283.
    1. An W. S., Kim H. J., Cho K.-H., Vaziri N. D. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. American Journal of Physiology-Renal Physiology. 2009;297(4):F895–F903. doi: 10.1152/ajprenal.00217.2009.
    1. Tayyebi-Khosroshahi H., Houshyar J., Dehgan-Hesari R., et al. Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-alfa in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2012;23(3):500–506.
    1. Giunti S., Tesch G. H., Pinach S., et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia. 2008;51(1):198–207. doi: 10.1007/s00125-007-0837-3.
    1. Haller H., Bertram A., Nadrowitz F., Menne J. Monocyte chemoattractant protein-1 and the kidney. Current Opinion in Nephrology and Hypertension. 2016;25(1):42–49. doi: 10.1097/MNH.0000000000000186.
    1. Deshmane S. L., Kremlev S., Amini S., et al. Monocyte Chemoattractant Protein-1 (MCP-1): an overview. Journal of Interferon & Cytokine Research. 2009;29(6):313–326.
    1. Naini A. E., Asiabi R. E., Keivandarian N., Moeinzadeh F. Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. Advanced Biomedical Research. 2015;10(4):167–172. doi: 10.4103/2277-9175.162544.
    1. Madsen T., Schmidt E. B., Christensen J. H. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. Journal of Renal Nutrition. 2007;17(4):258–263. doi: 10.1053/j.jrn.2007.03.003.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren